Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Reaffirmed by Wedbush

Wedbush reiterated their outperform rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a research report sent to investors on Wednesday morning, RTT News reports. The brokerage currently has a $33.00 price target on the stock. Wedbush also issued estimates for Day One Biopharmaceuticals’ Q3 2025 earnings at ($0.32) EPS and FY2025 earnings at ($1.40) EPS.

Several other research firms have also commented on DAWN. Piper Sandler reaffirmed an overweight rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. Needham & Company LLC increased their price objective on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a buy rating in a report on Wednesday. HC Wainwright reissued a buy rating and issued a $50.00 price objective on shares of Day One Biopharmaceuticals in a report on Wednesday. The Goldman Sachs Group decreased their price objective on Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating for the company in a report on Tuesday, February 27th. Finally, Oppenheimer reissued a market perform rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Day One Biopharmaceuticals presently has a consensus rating of Moderate Buy and an average target price of $39.33.

Day One Biopharmaceuticals Trading Up 12.9 %

NASDAQ:DAWN opened at $14.92 on Wednesday. The firm has a market capitalization of $1.30 billion, a PE ratio of -6.27 and a beta of -1.48. The stock has a 50 day moving average of $15.22 and a 200-day moving average of $13.81. Day One Biopharmaceuticals has a 52 week low of $9.67 and a 52 week high of $17.85.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07). As a group, analysts predict that Day One Biopharmaceuticals will post -2.67 EPS for the current fiscal year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 2,666 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $40,656.50. Following the completion of the transaction, the chief financial officer now directly owns 277,754 shares of the company’s stock, valued at approximately $4,235,748.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 2,666 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $40,656.50. Following the completion of the transaction, the chief financial officer now directly owns 277,754 shares of the company’s stock, valued at approximately $4,235,748.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Samuel C. Blackman sold 10,000 shares of the stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $16.02, for a total value of $160,200.00. Following the transaction, the insider now directly owns 1,174,662 shares of the company’s stock, valued at $18,818,085.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,781 shares of company stock valued at $883,160. 8.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several large investors have recently modified their holdings of DAWN. China Universal Asset Management Co. Ltd. boosted its stake in shares of Day One Biopharmaceuticals by 130.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock worth $27,000 after acquiring an additional 1,262 shares in the last quarter. Quest Partners LLC bought a new stake in shares of Day One Biopharmaceuticals during the 4th quarter worth $29,000. Quintet Private Bank Europe S.A. boosted its stake in shares of Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after acquiring an additional 1,000 shares in the last quarter. Amalgamated Bank boosted its stake in shares of Day One Biopharmaceuticals by 35.7% during the 3rd quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock worth $106,000 after acquiring an additional 2,268 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its stake in shares of Day One Biopharmaceuticals by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock worth $147,000 after acquiring an additional 2,554 shares in the last quarter. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.